Dr. Reiter is the Bing Professor of Urologic Oncology and Chief of the Division of Urologic Oncology. He attended Stanford Medical School, completed his urologic training at Stanford and Baylor College of Medicine, and completed additional fellowship training in urological cancer at the National Cancer Institute. Dr. Reiter was awarded the Outstanding Achievement Award by the Urologic Oncology branch of the National Cancer Institute. Dr. Reiter is an internationally recognized expert in all areas of prostate cancer management and research. He was among the first to integrate functional MRI imaging and PSMA PET imaging into the diagnosis, surgical management, and care of men with prostate cancer. He was also an early innovator in the field of robotic surgery, and has completed more than 2,500 robotic prostatectomies. In addition to surgical management of prostate cancer, Dr. Reiter has expertise in MRI-guided biopsies to diagnose prostate cancer, focal therapy to treat select individuals, as well as all forms of medical therapy. Dr. Reiter has a particular interest in the multidisciplinary management of men with high-risk prostate cancer, incorporating the latest in genomics, clinical trials, and precision medical therapies into treatment plans in collaboration with UCLA leaders in the areas of radiation, medical and nuclear prostate oncology. In addition to his broad clinical interests in prostate cancer, Dr. Reiter is a leading researcher in prostate cancer and has led UCLA’s 12 million SPORE grant, which supports work to translate laboratory discoveries into clinical advances, for more than 15 years. Drugs such as enzalutamide and apalutamide, and imaging tools such as PSMA PET, are among the many advances that have emanated from this program. His own laboratory discovered the prostate stem cell antigen and developed antibodies to target this protein, which has led to novel imaging and therapeutic approaches for prostate cancer currently in clinical trials. Dr. Reiter has authored more than 250 papers and lectures nationally and internationally on all aspects of clinical care of men with prostate cancer.

Jacob See-Tong Pang is Director of Urology at Chang Gung Memorial Hospital in Taiwan. He was president of the Taiwan Urological Oncology Association from 2016-2018 and vice president of the Taiwan Urological Association from August 2018. His research effort focuses on understanding and improving clinical outcomes of patients with urological cancer. He has published numerous peer-reviewed articles in many renowned medical journals. His research work has been recognized by international committees and he received the 2018 American Association for Cancer Research science team award.

David F. Penson, MD, MPH is the Hamilton and Howd Chair in Urologic Oncology, Director of the Center for Surgical Quality and Outcomes Research and Professor and Chair, Department of Urology at Vanderbilt University Medical Center. He obtained his MD from Boston University and completed his urology residency at UCLA Medical Center in Los Angeles. He then was awarded a Robert Wood Johnson Clinical Scholar fellowship at Yale University and also obtained an MPH at Yale. He currently maintains a clinical practice in urologic oncology at the Vanderbilt-Ingram Cancer Center. His specific research interests include the comparative effectiveness of treatment options in localized prostate cancer and the impact of the disease and its treatment on patients’ quality of life. He has received federal grant funding from the National Cancer Institute, the US Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention and the Patient-Centered Outcomes Research Institute. His work has been published in various high-profile journals, including the New England Journal of Medicine, JAMA and the Annals of Internal Medicine. He previously chaired the National Institutes of Health’s Health Services Outcomes and Delivery (HSOD) study section, which reviews almost all health services research grant submitted to the NIH. He also maintains a strong interest in health policy and quality improvement. He currently serves as the Secretary of the American Urological Association.

Prof. Arun Azad is a medical oncologist based in Melbourne, Australia at Peter MacCallum Cancer Centre and University of Melbourne focused on clinical and translational research in prostate cancer. He has past and ongoing leadership positions in numerous prostate cancer clinical trial steering committees serving as Co-Chair of 3 global phase III trials. He holds key leadership roles including Translational Chair at ANZUP Cancer Trials Group and Urologic Oncology Chair at Clinical Oncology Society of Australia and sits on the ESMO Clinical Practice Guidelines for Prostate Cancer.

Dr Veronica Wong is a nuclear medicine physician at the Nepean Hospital in NSW.

Dr Aviral Singh is the Clinical Head of Theranostics & Nuclear Medicine at GenesisCare Australia and based in Perth, Western Australia. Aviral is an active research physician and Investigator for several multicentre clinical trials in Theranostics. He has published over 45 peer-reviewed scientific papers and serves on the Guest Editorial Board for the Frontiers journals in Endocrinology and Nuclear Medicine. His recognitions include the prestigious ‘Ones to Watch’ at SNMMI 2022, USA, inclusion in the Global Physician Honor Roll of GenesisCare in 2022, listing as a Leading World Physician of IAHCP in 2017, in addition to receiving best scientific paper awards at the SNMMI 2016 and the ICRT in 2019 and 2024. He has presented keynote and invited lectures at several scientific society meetings nationally and internationally. Aviral serves as a member of the Governing Body of the World Association of Radiopharmaceutical and Molecular Therapy.